Eli Lilly lower afterhours on White House comments, says Cantor Fitzgerald

Cantor Fitzgerald keeps an Overweight rating and $925 price target on Eli Lilly (LLY). The White House / FDA joint media conference this afternoon saw the administration unveiled the first nine drugs selected to receive the new Commissioner’s National Priority Vouchers, and notably, the company’s orforglipron was not included. The disclosure, though not yet finalized, also comes against the backdrop of vague and at times contradictory GLP-1 pricing commentary, Cantor added, including statements by Trump that the cost of GLP-1 drugs would come down ‘pretty fast’.